Irene Ng Oi Lin 吳呂愛蓮

  • Senior Medical Research Fellowship in 2013 at University of Hong Kong
  • Senior Medical Research Fellowship in 2005 at University of Hong Kong

Professor Irene Ng Oi Lin is Loke Yew Professor in Pathology and Chair Professor of the Department of Pathology at The University of Hong Kong. She is also the Director of the State Key Laboratory for Liver Research at The University of Hong Kong. In addition, Professor Ng served as Head of the Department (HKU) (2011-2019) and Chief of Service of Department of Pathology at Queen Mary Hospital (2017-2019). She is internationally recognized for her expertise in research in liver cancer (hepatocellular carcinoma), particularly in molecular genetics and patho-biology. Among her achievements have been the identification and characterization of novel genes, signaling pathways and cancer stem cells of this cancer. These studies have provided important insight in the understanding of hepatocarcinogenesis and help to identify potential targets in novel cancer therapy. She ranks among the world’s top 1% in the Institute for Scientific Information (ISI) list of most cited scientists in clinical medicine.


Professor Ng's laboratory aims to unravel the molecular and cellular mechanisms of liver cancer. Prof Ng and her team are focusing on the integrated functional genomics of liver cancer using genome-scale technologies coupled with clinical translational studies. They are working on an active program in the basic/translational research of liver cancer, using state-of-the art molecular approaches including genomics, transcriptomics, and single cell analysis, to capture cancer heterogeneity, identify novel subclones, and unravel signaling pathways. The team couples genomics, genetics, functional molecular analysis and in vivo pre-clinical animal models as well as patient-derived tumor xenograft models to address the molecular mechanisms of this cancer. They work towards translational application for early detection, diagnosis, prognosis and patient stratification towards precision oncology.